- December 2016
Joao Incio on mechanisms to explain why obesity promotes cancer.
- November 2016
Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
- October 2016
Ruth Muschel on a new target for treatments for colorectal cancer.
- September 2016
Freddie Hamdy on the effectiveness of treatments for prostate cancer.
- August 2016
Moshe Oren discusses the effects of the microenvironment on cancer cells.
- July 2016
Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
- June 2016
Key advances in clinical trials.
- May 2016
Mark Lemmon on the underlying biochemistry of cancer.
- April 2016
Roger Stupp on using alternating electric fields as treatment.
- March 2016
Charlotte Vrinten on public perception of deaths from cancer.
- February 2016
Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
- December 2015/January 2016
Nazneen Rahman on germline genetic screening in ovarian cancer.
EJC News Focus – February 2016
Unravelling the mysteries of MDS
All cancers have some epigenetic component, but myelodysplastic syndromes (MDS) are the only diseases in which hypomethylating agents have had significant clinical activity. Colon cancer, for example has as much methylation as MDS but is resistant to these agents. Why that should be remains a mystery.
At the European Cancer Congress in Vienna (September 2015), Guillermo Garcia-Manero (MD Anderson Cancer Center, Houston, Texas) presented research into this and other difficult questions in MDS. In this EJC News Focus, he tells Helen Saul that the eventual answers could have implications in a wide range of cancers.